Boehringer Ingelheim GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Boehringer Ingelheim GmbH
Four orphan drugs and a new COVID-19 vaccine are among the latest products that the European Medicines Agency says should be approved.
India’s COVID-19 immunization focus has shifted to children as over 88% adults are fully vaccinated. However, Scrip’s examination of weekly data reveals the number of doses given to children are also dropping sharply off peaks. Meanwhile, Biological E is winning over others like Novavax in this segment while Zydus Lifesciences is yet to score
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
Acknowledging the toll that vaccine opponents have taken on FDA operations, the CBER director emphasizes the need to create stand-by manufacturing capacity, conduct faster studies in special populations, and better understand the mRNA platform.
- Other Names / Subsidiaries
- Abexxa Biologics Inc
- AMAL Therapeutics SA
- ICD Therapeutics
- NBE Therapeutics AG
- SSP Co., Ltd.
- Vira Therapeutics GmbH (Vira T)